



> Int J Immunopathol Pharmacol. Jul-Sep 2013;26(3):825-31. doi: 10.1177/039463201302600332.

FULL TEXT LINKS

SAGE journals

Open access full text

Combination therapy including serratiopeptidase improves outcomes of mechanical-antibiotic treatment of periimplantitisG Sannino ¹, P Gigola, M Puttini, F Pera, C Passariello

Affiliations + expand

PMID: 24067485 DOI: [10.1177/039463201302600332](https://doi.org/10.1177/039463201302600332)

Free article

Abstract

This study was designed as a retrospective analysis of clinical outcomes of cases of periimplantitis treated by mechanical debridement and the administration of antibiotics combined or not with the administration of either the proteolytic enzyme serratiopeptidase (SPEP) or non-steroidal anti-inflammatory drugs (NSAIDs). Clinical charts of 544 partially edentulous patients treated for periimplantitis between June 1996 and December 2010 were analyzed to obtain clinical data of the affected implants just before the beginning of treatment and 12 months later to evaluate the outcomes of combined mechanical antibiotic treatment alone or in combination with the co-administration of the anti-inflammatory SPEP or NSAIDs. The comparative analysis revealed that therapeutic outcomes were significantly different in the three groups. Failure rate in the group that received SPEP (6 percent) was significantly lower compared to the group that received NSAIDS (16.9 percent; P less than 0.01) and to the group that received no anti-inflammatory therapy (18.9 percent; P less than 0.01). Treatment including SPEP was associated with significantly better healing also when successful treatments alone were considered. The data reported in this paper strongly support the hypothesis that SPEP is a valid addition to protocols for the combined therapy of peri-implantitis. In fact, it allows to enhance success rates significantly and also favors better tissue repair around successfully treated implants as compared to other regimens.

Similar articles[Anti-infective therapy of peri-implantitis with adjunctive local drug delivery or photodynamic therapy: six-month outcomes of a prospective randomized clinical trial.](#)

Schär D, Ramseier CA, Eick S, Arweiler NB, Sculean A, Salvi GE.

Clin Oral Implants Res. 2013 Jan;24(1):104-10. doi: 10.1111/j.1600-0501.2012.02494.x. Epub 2012 May 9.

PMID: 22568744 Clinical Trial.

[Clinical efficacy of antibiotics in the treatment of peri-implantitis.](#)

Javed F, Alghamdi AS, Ahmed A, Mikami T, Ahmed HB, Tenenbaum HC.

Int Dent J. 2013 Aug;63(4):169-76. doi: 10.1111/idj.12034. Epub 2013 Apr 9.

PMID: 23879251 Review.

[Surgical Treatment of Implants Affected by Periimplantitis After 15 Years of Loading: A Case Report.](#)

Nicolli LG, Pigossi SC, Marcantonio C, Leal Zandim-Barcelos D, Marcantonio E Jr.

Implant Dent. 2016 Apr;25(2):288-92. doi: 10.1097/ID.0000000000000398.

PMID: 26910186

[Nonsurgical Treatment of Periimplantitis.](#)

Wang CW, Renvert S, Wang HL.

Implant Dent. 2019 Apr;28(2):155-160. doi: 10.1097/ID.0000000000000846.

PMID: 30913111 Review.

[Photodynamic therapy to treat periimplantitis.](#)

Bombecari GP, Guzzi G, Gualini F, Gualini S, Santoro F, Spadari F.

Implant Dent. 2013 Dec;22(6):631-8. doi: 10.1097/ID.0000433592.18679.91.

PMID: 24225780 Clinical Trial.

[See all similar articles](#)**Cited by** 6 articles[Direct-Deposited Graphene Oxide on Dental Implants for Antimicrobial Activities and Osteogenesis.](#)

Jang W, Kim HS, Alam K, Ji MK, Cho HS, Lim HP.

Int J Nanomedicine. 2021 Aug 24;16:5745-5754. doi: 10.2147/IJN.S319569. eCollection 2021.

PMID: 34471350 [Free PMC article.](#)

No abstract available.

[Serratiopeptidase, A Serine Protease Anti-Inflammatory, Fibrinolytic, and Mucolytic Drug, Can Be a Useful Adjuvant for Management in COVID-19.](#)

Sharma C, Jha NK, Meeran MFN, Patil CR, Goyal SN, Ojha S.

Front Pharmacol. 2021 Jun 24;12:603997. doi: 10.3389/fphar.2021.603997. eCollection 2021.

PMID: 34248612 [Free PMC article.](#)

No abstract available.

[Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial.](#)

Tamimi Z, Al Habashneh R, Hamad I, Al-Ghazawi M, Roqa'a AA, Kharashgeh H.

BMC Oral Health. 2021 Mar 2;21(1):91. doi: 10.1186/s12903-021-01451-0.

PMID: 33653320 [Free PMC article.](#) Clinical Trial.[Serratiopeptidase: Insights into the therapeutic applications.](#)

Jadhav SB, Shah N, Rathi A, Rathi V, Rathi A.

Biotechnol Rep (Amst). 2020 Oct 17;28:e00544. doi: 10.1016/j.btre.2020.e00544. eCollection 2020 Dec.

PMID: 33134103 [Free PMC article.](#) Review.[The role of serratiopeptidase in the resolution of inflammation.](#)

Tiwari M.

Asian J Pharm Sci. 2017 May;12(3):209-215. doi: 10.1016/j.ajps.2017.01.003. Epub 2017 Feb 1.

PMID: 32104332 [Free PMC article.](#) Review.[See all "Cited by" articles](#)**Publication types**[> Letter](#)[> Research Support, Non-U.S. Gov't](#)**MeSH terms**[> Anti-Bacterial Agents / therapeutic use*](#)
[> Anti-Inflammatory Agents, Non-Steroidal / adverse effects*](#)
[> Combined Modality Therapy](#)[> Debridement*](#)[> Drug Therapy, Combination](#)[> Humans](#)[> Peptide Hydrolases / therapeutic use*](#)[> Peri-Implantitis / diagnosis](#)[> Peri-Implantitis / drug therapy*](#)[> Peri-Implantitis / surgery*](#)[> Retrospective Studies](#)[> Time Factors](#)[> Treatment Outcome](#)[> Wound Healing / drug effects](#)**Substances**[> Anti-Bacterial Agents](#)
[> Anti-Inflammatory Agents, Non-Steroidal](#)
[> Peptide Hydrolases](#)
[> serratiopeptidase](#)**Related information**[MedGen](#)**LinkOut – more resources**[Full Text Sources](#)[Atypon](#)[Other Literature Sources](#)[scite Smart Citations](#)[Medical](#)[MedlinePlus Health Information](#)